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Effects of cyclosporin, nifedipine and 
phenytoin on gingival myofibroblast 
transdifferentiation in monkeys
Objective: Myofibroblasts have been associated with the development 
of several pathologic fibrotic conditions. This longitudinal study aims to 
assess the proliferative and antiapoptotic effects of cyclosporin, nifedipine 
and phenytoin on gingival connective tissue cells of nonhuman primate, as 
well as to analyze a possible role of myofibroblasts in gingival overgrowth. 
Materials and Methods: Gingival samples from the right superior canine area 
were obtained from 12 male monkeys (Sapajus spp) to comprise the control 
group. After one week, the animals were randomly assigned to three groups, 
which received daily oral doses of cyclosporin, nifedipine or phenytoin for 
120 days. Gingival samples were collected from the left superior canine area 
of two animals of each group at 52 and 120 days. Histological sections were 
stained with hematoxylin and eosin, and immunoreacted against α-SMA, Ki-
67 and bcl-2. Results: α-SMA immunoreaction was negative in the control 
and experimental groups. Similarly, no difference between groups concerning 
immunostaining against Ki-67 and bcl-2 was observed in connective tissue 
cells. Conclusion: Based on this methodology, it may be concluded that 
gingival overgrowths induced by cyclosporin, nifedipine and phenytoin are 
not associated with neither myofibroblast transdifferentiation, proliferation 
nor apoptosis of gingival connective cells in monkeys.
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Introduction
Drug-induced gingival overgrowth (GO) is an 
unwanted side effect that has been mainly associated 
with chronic therapy with phenytoin, nifedipine and 
cyclosporin (CsA). This condition is characterized by 
gingival enlargement due to alterations in cellular 
and extracellular matrix (ECM) metabolisms, leading 
to accumulation of several components of ECM.1-2 
However, the inducing molecular mechanisms remain 
unknown in many aspects.
The development of GO involves changes in the 
metabolism of several cellular types, in a complex 
interdependent reaction in cascade.2-4 However, 
fibroblasts have been the main cell studied, as they 
are responsible for the synthesis and enzymatic 
degradation of ECM proteins.3,5-9 Fibroblasts derived 
from phenytoin-induced GO exhibit higher proliferative 
activity10 and elevated levels of collagen synthesis11 
compared with cells obtained from normal gingiva. 
This fact raised the hypothesis that phenytoin exerts 
a selective pressure favoring the proliferation of a 
specific fibroblastic subpopulation, which eventually 
becomes the predominant cell type in the tissue. 
Ultrastructural analysis of “modified” fibroblasts of GO 
induced by phenytoin showed morphological features 
compatible with myofibroblasts.12
Myofibroblast is considered the main cellular type 
involved in extracellular matrix deposition during 
tissue remodeling. This cell population is characterized 
by the expression of α-smooth muscle actin (α-SMA). 
After the completion of physiological events, such as 
wound healing, the reversion of myofibroblasts does 
not seem to be possible, and massive apoptosis has 
been described.13 Myofibroblast apoptosis is critical for 
normal healing as its persistence favors a continuous 
ECM deposition and the development of pathologic 
fibrotic conditions.14
CsA, phenytoin and nifedipine induce fibrosis not 
only in gingival tissue, but also in important organs 
that may present a resultant loss of function. Studies in 
rats showed increased levels of α-SMA immunostaining 
in kidneys15-16 and pancreas17 after therapy with CsA. 
Additionally, Dill & Iacopino12 (1997) described cells 
with ultrastructural features of myofibroblasts in 
liver, spleen and mesentery of rats, after phenytoin 
administration. These facts raise the question of 
whether CsA, phenytoin and nifedipine might induce 
myofibroblast transdifferentiation and proliferation 
in GO.
GO is a multifactorial lesion that involves complex 
and interdependent interactions among different cell 
types.3-4 For this reason, important new insights may 
be gained into GO pathogenesis with in vivo studies, 
employing standardized time of analysis. Therefore, 
the aim of this study was to analyze the effects 
of CsA, nifedipine and phenytoin on myofibroblast 
transdifferentiation, proliferation and resistance to 
apoptosis in gingival tissue of tufted capuchin monkeys 
(Sapajus spp).
Material and methods
The experimental protocol of this study was 
approved by the Committee of Ethics in Animal 
Experiment (Protocol 41/03). This study is part of a 
series of researches carried out on the same material 
and followed the Guide for the Care and Use of 
Laboratory Animals.
Twelve healthy male tufted capuchin monkeys 
(Sapajus spp) were used in this study. This animal 
model was used for its anatomical similarity and 
phylogenetic proximity to human. They were 
maintained in individual steel cages, with natural 
light and fresh air during the day and under artificial 
warming during cold nights. Their diet was based on 
fruits, vegetables, yogurt, eggs and water ad libitum.
Before surgery, the animals were sedated and 
anesthetized with intraperitoneal injection of sodium 
thionembutal (Abbot Laboratories, Chicago, IL, USA) 
at 30 mg/kg body weight. Surgical sites were classified 
according to the criteria for Sulcus Bleeding Index 
by Mühlemann and Mazor18 (1958) and anesthetized 
with routine dental infiltration anesthesia with 2% 
mepivacaine with 1:100,000 adrenaline (Mepiadre®, 
DFL, Rio de Janeiro, RJ, Brazil). Gingival samples, 
comprised of free and attached gingiva, were obtained 
from the right superior canine area of all animals, 
which constituted the control group. The vertical 
incisions included the mesial and distal interdental 
papillae on the buccal side and were completed with 
an apical incision at the mucogingival junction.
The animals were randomly assigned to three 
experimental groups one week after the control 
biopsy (n=4). Group I was treated with daily oral 
doses of 5 mg/kg of CsA (Novartis Pharma AG, Basle, 
Switzerland) whereas Group II received 7.5 mg/kg 
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of phenytoin (Apothicario, Araçatuba, SP, Brazil). 
One week after beginning the drug administration, 
the dosage of both medications was increased to 15 
mg/kg. The gradual increase in drug dosage allowed 
observation of possible toxic effects as no previous 
study in drug safety in this animal model was found, 
especially regarding phenytoin. The determination 
of final CsA dose was based on the recommended 
human posttransplant dosage. Group III received 
daily oral doses of 40 mg/kg of nifedipine (Apothicario, 
Araçatuba, SP, Brazil) during the whole experimental 
period. The drugs were diluted in yogurts and provided 
once a day.
Gingival specimens were obtained from the left 
superior canine area of two animals of each group on 
the 52nd day. The experimental period was concluded 
on the 120th day, when samples were obtained from the 
left superior canine area of all animals not subjected 
to biopsy on the 52nd day. Sampling was performed 
at the opposite side of the first biopsy to avoid the 
interference of wound healing. The biopsy on the 52nd 
and 120th days followed the same protocol of the first 
sampling procedure, except for the use of ketamine 
(Cristalia Produtos Químicos Farmacêuticos Ltda, 
Itapira, SP, Brazil) at 10 mg/kg, as general anesthetic.
The animals were observed during the whole 
experimental period in the search for possible adverse 
effects of drug therapy. Clinical images were registered 
on the three days of tissue sampling.
Immunohistochemical study
Gingival samples were fixed in 10% formalin 
solution, paraffin embedded and sectioned in 
buccolingual plane, following the tooth long axis. 
6-µm-thick sections were stained with hematoxylin 
and eosin for morphologic analyses of epithelial and 
connective tissues.
For immunohistochemical study, 3-µm-thick 
sections were deparaffinized and subjected to 
epitope retrieval in steamer. For α-SMA study, the 
slides were maintained in citrate buffer at 60°C for 
20 minutes. Tris-EDTA at initial temperature of 60°C 
and then heated to 95°C for 20 minutes was used as 
buffer solution before the proliferation marker, Ki-67 
primary antibody, and bcl-2 immunoreactions for the 
assessment of resistance to apoptosis. Overnight 
incubation was carried out at 4°C with the following 
dilutions of primary antibodies: Monoclonal mouse 
anti-human α-SMA (M0851) 1:200 (Dako Corp., 
Carpenteria, CA, USA), Monoclonal mouse anti-
human bcl-2 (M0887) 1:50 (Dako Corp., Carpenteria, 
CA, USA) and Monoclonal mouse anti-human Ki-67 
(M7240) 1:100 (Dako Corp., Carpenteria, CA, USA). 
Sections were washed in tris-buffered saline and 
incubated with streptavidin complex with biotinylated 
horseradish peroxidase (Dako Corp., Carpenteria, 
CA, USA) for 30 minutes, then diaminobenzidine 
(Dako Corp., Carpenteria, CA, USA) was used as a 
chromogen.
Fast green dye (Dako Corp., Carpenteria, CA, 
USA) was used as a counterstain, except for samples 
reacted against bcl-2 in which hematoxylin was 
used. As negative control, gingival sections from 
tufted capuchin monkeys were subjected to the same 
immunohistochemical reaction protocol, without the 
primary antibody. Positive control reactions for bcl-2 
and Ki-67 were carried out in spleen and/or tonsils 
of monkeys of the same species. Immunoreaction 
in blood vessels was considered a positive internal 
control for α-SMA.
Histological images were captured for analysis 
in a computer program for image processing 
(Leica Microsystems, Heerbrugg, Switzerland). Two 
representative sections of each animal relative to 
the periods under study were analyzed at 200x 
magnification. Fibroblast-like cells were counted 
in HE sections in three different connective tissue 
sites, with corresponding areas of 600.000 µm2: 
subjacent to oral epithelium (OE), sulcular epithelium 
(SE) and middle-deep area (MD). Cell counting was 
blinded performed in two different occasions by two 
independent examiners. Myofibroblast cell counting 
followed the same protocol.
Results
Clinical observations
The experimental period elapsed without any 
intercurrence. No clinical or behavioral modification 
that could be attributed to drug administration or its 
systemic side effects was observed.
At the initial phase (control group), subtle signs of 
gingival inflammation were observed, usually limited 
to the free gingival margins.
Gingival enlargement was observed in all animals, 
in a variety of severity grades and more prominent 
in anterior areas. CsA induced the most prominent 
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enlargement, observable from the second week of 
drug administration. No significant difference between 
control and treated groups was found with regard the 
Sulcus Bleeding Index (Figure 1), although a tendency 
for lower values was observed in some control groups.
Histomorphological study
Control transversal sections disclosed clearly 
distinctive layers of connective tissue. The papillary 
layer of lamina propria was consisted of loose 
connective tissue with a profuse capillary network. 
Deeper to this layer, an extensive area of dense 
irregular connective tissue, with thick bundles of 
collagen fibers was observed. This reticular layer 
presented larger blood vessels enclosed in isolated 
areas of loose connective tissue, centrally and deeply 
situated. In the area of junctional epithelium, the 
underlying connective tissue frequently showed varied 
inflammatory infiltrate grades.
The histological aspects were maintained on 52-
day samples of all experimental groups, except for 
the visibly enlarged extension of the sections at the 
macroscopic level. Occasionally, the lamina propria 
underlying the oral epithelium presented a longer and 
larger papillae, despite the drug administrated. This 
histological feature was more prominent on the 120-
day samples of all the experimental groups. Statistical 
analysis did not disclose differences in mean values 
of fibroblast-like cell counting between periods in the 
three experimental groups (Figure 2).
Immunohistochemical analysis
Ki-67 immunostaining was detected in a scattered 
and non-uniform pattern in the nucleus of basal 
epithelial cells of some samples of the control group. 
Conversely, this immunostaining was constant 
and profuse in blood vessel cells, especially in the 
papillary layer (Figure 3C). The same pattern of 
epithelial immunostaining was infrequently observed 
in the treated groups, and even more limited in 
the connective tissue (Figure 3D). No reaction was 
detected in the negative control samples.
α-SMA immunostaining was restricted to the 
cytoplasm of endothelial cells and was more evident 
in medium-diameter arteries and veins. These vessels 
had a profuse distribution in the connective tissue of 
the papillary and reticular layers of lamina propria. 
No additional labeling was detected in any other cell 
type, neither in the control (Figure 3E) nor in the 
treated samples in the three experimental periods 
(Figure 3F). The absence of myofibroblasts precluded 
statistical analysis.
A sparse distribution of bcl-2 immunostaining 
was observed in the cytoplasm of epithelial cells of 
Figure 1- Sulcus Bleeding Index at days 0 (Control), 52 and 120. Medium values of three points of measurement at the buccal side of 
superior canines
Figure 2- Fibroblast-like cell counting at days 0 (Control), 52 and 120. Medium values of three areas with 600.000 mm2: subjacent to oral 
epithelium, sulcular epithelium and middle-deep area
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the control samples (Figure 4E). No immunostaining 
was detected in this area in samples of the treated 
groups, in any experimental period (Figure 4F). 
In some sections, the reaction against bcl-2 was 
observed in non-uniform pattern in different layers 
of the epithelium relative to the sulcular area and 
its underlying connective tissue, supposedly in 
inflammatory cells. This detection varied according to 
the severity of inflammatory infiltration in this area in 
different animals and it was not correlated with any 
drug administered. The positive control consisted of 
immunoreactions in the germinal center of spleen and 
lymph nodes. No reaction was detected in negative 
controls.
Discussion
To the best of our knowledge, this study marks the 
first time that a possible myofibroblast participation 
in the development of GO induced by nifedipine, 
phenytoin or CsA is longitudinally assessed in a 
nonhuman primate.
In vitro studies with gingival fibroblasts described 
an increase in α-SMA expression induced by CsA, 
associated with the upregulation of TGF-β1 gene 
expression.19 This cytokine is a potent inducing factor 
for myofibroblast transdifferentiation13 and protects 
them from apoptosis.14 Parallelly, in vivo studies found 
Figure 3- Ki-67 and α-SMA immunostaining. (A) Ki-67 immunostaining in positive control in histological section of lymph node of capuchin 
monkey (Sapajus spp). Original Magnification x20. (B) Negative control in histological section of gingiva of capuchin monkey. Fast green 
dye counterstaining. (C) Immunoreaction against Ki-67 in buccolingual transversal section of gingival sample of the control group. Fast 
green dye counterstaining. (D) Immunoreaction against Ki-67 in buccolingual transversal section of gingival sample of phenytoin group, 
120 days. Fast green dye counterstaining. (E) Immunostaining against α-SMA in gingival sample of the control group. Fast green dye 
counterstaining. Original Magnification x10. (Bar=50 mm) (F) Immunoreaction against α-SMA in gingival sample of the CyA group (52 
days). Positive reaction in blood vessels. Fast green dye counterstaining
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a correlation between the fibrosis induced by CsA in 
kidneys15,16 and pancreas of rats17 with an increase 
in α-SMA immunostaining. Then, the association 
between myofibroblast proliferation and GO seemed 
to be plausible. However, this hypothesis could not 
be proven true in this assay, similarly to a previous in 
vivo study with CsA in rats.20
The molecular pathways of myofibroblast 
differentiation involve a combined set of cytokines, 
growth factors, ECM composition and mechanic 
tension, molecules on cellular surface that, among 
other factors,15 may not be associated with GO. 
Drug effects vary according to the cell type. 
Myofibroblasts are, presumably, originated from 
preexisting fibroblasts, perivascular fibroblasts and 
pericytes,21 endothelial cells,22 stem cells from bone 
marrow23 and epithelial cells.16 It is not clear whether 
different origins of myofibroblasts are correlated with 
different biological events, such as normal tissue 
repair and pathological fibrosis,15 or even, whether 
myofibroblasts in different organs are derived from 
specific cellular sources. Moreover, the resultant tissue 
response is still a consequence of a complex interaction 
between local microenvironment conditions, a set of 
paracrine factors provided by specific neighboring 
cells, ECM composition and integrins.15
S igna l i ng  pa thways  f o r  myo f i b rob las t 
transdifferentiation induced by CyA are active in 
gingival fibroblasts.19 However, they seem to be 
expressed in lower levels by gingival fibroblasts 
Figure 4- Photomicrographs of hematoxylin and eosin and bcl-2 immunostaining. (A) Gingival sample of the control group. HE. (Bar=50 
mm). (B) Gingival sample of the phenytoin group, 120 days. In detail, fibroblast-like cell (arrow). (C) Positive control of bcl-2 immunoreaction 
in histological section of spleen of capuchin monkey (Sapajus spp). Original Magnification x10. (D) Negative control in histological section 
of gingiva of capuchin monkey. Hematoxylin counterstaining. Original Magnification x20. (E) Immunoreaction against bcl-2 in gingival 
sample of the control group. Fast green dye counterstaining. (F) Immunoreaction against bcl-2 in gingival sample of the CyA group, 120 
days. Hematoxylin counterstaining
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maintained in three-dimensional culture,24 which 
indicates an inherent and genetically determined 
feature of this fibroblast phenotype.25 Therefore, 
increased rates of TGF-β1 induced by CyA19 as well 
as nifedipine and phenytoin,26 do not seem to be 
sufficient, by themselves, for the induction to in vivo 
myofibroblast trandifferentiation in GO.20 Anyway, 
elevated TGF-β1 levels are also characteristic of 
inflammatory processes, although the increase in this 
growth factor levels in GO cannot be explained solely 
by gingival inflammation10. Despite the controversies 
over the role of inflammation on GO pathogenesis, 
it tends to be consider an important contributing 
factor but not essential for the development of GOs.27 
Interestingly, myofibroblast proliferation by itself could 
not lead to fibrosis induced by CsA in pancreas of rats, 
and an inflammatory component was determinant for 
the increase in ECM components.17 In this study, no 
correlation was found between GO development and 
the Sulcus Bleeding Index.
Fibroblast proliferation induced by CsA is directly 
proportional to the severity of inflammation as a 
decrease in immunostaining against Ki-67 occurs after 
the control of periodontal irritants.28 Consequently, an 
equivalent cellularity can be observed when normal 
gingiva and CsA-induced GO are compared.29 In this 
study, the restricted and low-intensity inflammation 
observed histologically may justify, at least partially, 
the limited immunostaining against Ki-67 in gingival 
connective tissue in all experimental groups, which 
is in accordance with the results of fibroblast-like cell 
counting.
The absence of myofibroblasts is compatible 
with the concept that GO develops mainly at the 
expense of a decrease in ECM degradation, more 
than the synthesis of its components. In this sense, 
decrease in collagenolytic activity induced by CsA3,7 
and phenytoin9,30 were described in the literature. 
Additionally, previous studies described a decrease 
in collagen amount or its gene expression induced by 
nifedipine,5,8 phenytoin1 and CsA.6
A question to be raised in this study is whether GO 
has completed its development under the experimental 
design as several studies indicated a phased evolution 
of GO.30-33 Studies in rats32,33 and cats30 described an 
initial, but transitory, increase in fibroblasts, followed 
by the return to previous rates of number of cells 
in relation to ECM. This fact may justify, at least in 
part, some contradictory results described previously 
in studies in which the changes in cell number were 
assessed in GOs. The aforementioned transitory 
increase in fibroblast number was not observed in this 
study, and the authors could not determine whether 
it occurs in this animal model.
Conclusions
Within the limits of this study, it can be concluded 
that CsA, nifedipine and phenytoin do not induce to 
myofibroblast transdifferentiation in gingival tissue of 
capuchin monkeys (Sapajus spp). The methodology 
also permitted concluding that these drugs do not 
have a proliferative or antiapoptotic effect on gingival 
connective cells. The results indicate that the fibrosis 
induced by the aforementioned drugs in different sites 
may have specific molecular pathways in a tissue-
dependent manner.
Acknowledgement
We would like to express our gratitude to the Tufted 
Capuchin Monkey Procreation Center (Univ. Estadual 
Paulista – UNESP, School of Dentistry, Araçatuba) for 
the kind assistance during the experimental period.
References
1- Dahllöf G, Modèer T, Reinholt FP, WikströM B, Hjerpe A. Proteoglycans 
and glycosaminoglycans in phenytoin-induced gingival overgrowth. J 
Periodontal Res. 1986;21(1):13-21.
2- Johanson M, Zhao XR, Huynh-Ba G, Vil lar CC. Matrix 
metalloproteinases, tissue inhibitors of matrix metalloproteinases, 
and inflammation in cyclosporine A-induced gingival enlargement: a 
pilot in vitro study using a three-dimensional model of the human oral 
mucosa. J Periodontol. 2013;84(5):634-40.
3- Cotrim P, Andrade CR, Martelli-Junior H, Graner E, Sauk JJ, Coletta 
RD. Expression of matrix metalloproteinases in cyclosporin-treated 
gingival fibroblasts is regulated by transforming growth factor (TGF)-
beta1 autocrine stimulation. J Periodontol. 2002;73(11):1313-22.
4- Cotrim P, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD. Cyclosporin 
A induces proliferation in human gingival fibroblasts via induction of 
transforming growth factor β-1. J Periodontol. 2003;74(11):1625-33.
5- Salo T, Oikarinen KS, Oikarinen AI. Effect of phenytoin and nifedipine 
on collagen gene expression in human gingival fibroblasts. J Oral Pathol 
Med. 1990;19(9):404-7.
6- Mariotti A, Hassell T, Jacobs D, Manning CJ, Hefti AF. Cyclosporin 
A and hydroxycyclosporine (M-17) affect the secretory phenotype of 
human gingival fibroblasts. J Oral Pathol Med. 1998;27(6):260-6.
7- Hyland PL, Traynor PS, Myrillas TT, Marley JJ, Linden GJ, Winter P, et 
al. The effects of cyclosporin on the collagenolytic activity of gingival 
fibroblasts. J Periodontol. 2003;74(4):437-45
KANNO CM, OLIVEIRA JA, ERVOLINO E, SOUBHIA AMP
J Appl Oral Sci. 2019;27:e201801358/8
8- Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Azuma H, Sawa T, et 
al. Nifedipine induces gingival overgrowth in rats through a reduction 
in collagen phagocytosis by gingival fibroblasts. J Periodontol. 
2001;72(8):1078-83.
9- Kato T, Okahashi N, Kawai S, Kato T, Inaba H, Morisaki I, et al. 
Impaired degradation of matrix collagen in human gingival fibroblasts 
by the antiepileptic drug phenytoin. J Periodontol. 2005;76(6):941-50.
10- Al-Ubaidy SS, Al-Janabi NY, Al-Tai SA. Effect of phenytoin on 
mitotic activity of gingival tissue and cultured fibroblasts. J Periodontol. 
1981;52(12):747-9.
11- Hassell TM, Page RC, Narayanan AS, Cooper CG. Diphenylhydantoin 
(Dilantin) gingival hyperplasia: drug-induced abnormality of connective 
tissue. Proc Natl Acad Sci U S A. 1976;73(8):2909-12.
12- Dill RE, Iacopino AM. Myofibroblasts in phenytoin-induced 
hyperplastic connective tissue in the rat and in human gingival 
overgrowth. J Periodontol. 1997;68(4):375-80.
13- Desmoulière A, Chaponnier C, Gabbiani G. Tissue repair, contraction, 
and the myofibroblast. Wound Repair Regen. 2005;13(1):7-12.
14- Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis 
by transforming growth factor β1. Am J Respir Cell Mol Biol. 
1999;21(6):658-65.
15- Ahmed A, Huang L, Raftery AT, Ahmed AK, Fahmy H, El Nahas AM, 
et al. Cyclosporine A sensitizes the kidney to tubulointerstitial fibrosis 
induced by renal warm ischemia. Transplantation. 2004;77(5):686-92.
16- Shin DH, Park HM, Jung KA, Choi HG, Kim JA, Kim DD, et al. The 
NRF2-heme oxygenase-1 system modulates cyclosporin A-induced 
epithelial-mesenchymal transition and renal fibrosis. Free Radic Biol 
Med. 2010;48(8):1051-63.
17- Vaquero E, Molero X, Tian X, Salas A, Malagelada JR. Myofibroblast 
proliferation, fibrosis, and defective pancreatic repair induced by 
cyclosporin in rats. Gut. 1999;45(2):269-77. 
18- Mühlemann HR, Mazor ZS. Gingivitis in Zürich school children. Helv 
Odont Acta. 1958;(2):3-12.
19- Chen J, Yang F, Yu X, Yu Y, Gong Y. Cyclosporine A promotes cell 
proliferation, collagen and α-smooth muscle actin expressions in rat 
gingival fibroblasts by Smad3 activation and miR-29b suppression. J 
Periodontal Res. 2016;51(6):735-47.
20- Sobral LM, Kellermann MG, Graner E, Martelli-Junior H, Coletta 
RD. Cyclosporin A-induced gingival overgrowth is not associated with 
myofibroblast transdifferentiation. Braz Oral Res. 2010;24(2):182-8.
21- Kramann R, Dirocco DP, Humphreys BD. Understanding the origin, 
activation and regulation of matrix-producing myofibroblasts for 
treatment of fibrotic disease. J Pathol. 2013;231(3):273-89.
22- Piera-Velazquez S, Mendoza F, Jimenez S. Endothelial to 
mesenchymal transition (EndoMT) in the pathogenesis of human fibrotic 
diseases. J Clin Med. 2016;5(4). pii: E45.
23- Mattoli S, Bellini A, Schmidt M. The role of a human hematopoietic 
mesenchymal progenitor in wound healing and fibrotic diseases and 
implications for therapy. Curr Stem Cell Res Ther. 2009;4(4):266-80.
24- Mah W, Jiang G, Olver D, Cheung G, Kim B, Larjava H, et al. 
Human gingival fibroblasts display a non-fibrotic phenotype distinct 
from skin fibroblasts in three-dimensional cultures. PLoS One. 
2014;;9(3):e90715.
25- Bahammam M, Black SA Jr, Sume SS, Assaggaf MA, Faibish M, 
Trackman PC. Requirement for active glycogen synthase kinase-3β 
in TGF-β1 upregulation of connective tissue growth factor (CCN2/
CTGF) levels in human gingival fibroblasts. Am J Physiol Cell Physiol. 
2013;305(6):C581-90.
26- Saito K, Mori S, Iwakura M, Sakamoto S. Immunohistochemical 
localization of transforming growth factor beta, basic fibroblast 
growth factor and heparan sulphate glycosaminoglycan in gingival 
hyperplasia induced by nifedipine and phenytoin. J Periodontal Res. 
1996;31(8):545-55.
27- Fu E, Hsieh YD, Shen EC, Nieh S, Mao TK, Chiang CY. Cyclosporin-
induced gingival overgrowth at the newly formed edentulous ridge 
in rats: a morphological and histometric evaluation. J Periodontol. 
2001;72(7):889-94.
28- Aimetti M, Romano F, Marsico A, Navone R. Non-surgical 
periodontal treatment of cyclosporin A-induced gingival overgrowth: 
immunohistochemical results. Oral Dis. 2008;14(3):244-50.
29- Buduneli N, Buduneli E, Cinar S, Lappin D, Kinane DF. 
Immunohistochemical evaluation of Ki-67 expression and apoptosis 
in cyclosporin A-induced gingival overgrowth. J Periodontol. 
2007;78(2):282-9.
30- Hassell TM, Roebuck S, Page RC, Wray SH. Quantitative 
histopathologic assessment of developing phenytoin-induced gingival 
overgrowth in the cat. J Clin Periodontol. 1982;9(5):365-72.
31- Kanno C, Oliveira J, Garcia J, Castro AL, Crivelini MM. Effects of 
cyclosporin, phenytoin, and nifedipine on the synthesis and degradation 
of gingival collagen in tufted capuchin monkeys (Cebus apella): 
histochemical and MMP-1 and -2 and collagen I gene expression 
analyses. J Periodontol. 2008;79(1):114-22.
32- Spolidório LC, Merzel J, Villalba H, Vargas PA, Coletta RD, Almeida 
OP. Morphometric evaluation of gingival overgrowth and regression 
caused by cyclosporin in rats. J Periodontal Res. 2001;36(6):384-9.
33- Spolidorio LC, Spolidorio DM, Holzhausen M. Effects of long-term 
cyclosporin therapy on the periodontium of rats. J Periodontal Res. 
2004;39(4):257-62.
Effects of cyclosporin, nifedipine and phenytoin on gingival myofibroblast transdifferentiation in monkeys
